Brokers Offer Predictions for Brainsway Q3 Earnings

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) – Research analysts at Northland Securities issued their Q3 2026 EPS estimates for shares of Brainsway in a research report issued to clients and investors on Thursday, January 22nd. Northland Securities analyst C. Byrnes expects that the company will earn $0.14 per share for the quarter. The consensus estimate for Brainsway’s current full-year earnings is $0.08 per share. Northland Securities also issued estimates for Brainsway’s Q4 2026 earnings at $0.16 EPS.

Brainsway (NASDAQ:BWAY) last announced its quarterly earnings data on Tuesday, November 11th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.03). Brainsway had a return on equity of 9.46% and a net margin of 12.73%.The firm had revenue of $13.51 million during the quarter, compared to the consensus estimate of $13.04 million.

BWAY has been the topic of a number of other research reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Brainsway in a research note on Monday, December 29th. Wall Street Zen cut shares of Brainsway from a “buy” rating to a “hold” rating in a report on Friday. Finally, HC Wainwright raised their price target on shares of Brainsway from $18.00 to $24.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Brainsway currently has an average rating of “Moderate Buy” and a consensus price target of $27.00.

Brainsway Stock Performance

Shares of NASDAQ BWAY opened at $23.04 on Monday. Brainsway has a fifty-two week low of $7.84 and a fifty-two week high of $24.84. The company has a market cap of $451.12 million, a price-to-earnings ratio of 76.80 and a beta of 1.19. The business’s 50 day moving average price is $18.88 and its 200-day moving average price is $16.13.

Hedge Funds Weigh In On Brainsway

A number of large investors have recently bought and sold shares of the business. Y.D. More Investments Ltd lifted its stake in shares of Brainsway by 559.8% during the fourth quarter. Y.D. More Investments Ltd now owns 114,962 shares of the company’s stock worth $2,187,000 after buying an additional 97,537 shares during the period. UBS Group AG raised its stake in Brainsway by 2,028.6% in the 3rd quarter. UBS Group AG now owns 63,878 shares of the company’s stock worth $963,000 after acquiring an additional 60,877 shares during the last quarter. Two Sigma Investments LP lifted its position in Brainsway by 25.2% during the 3rd quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock worth $1,551,000 after acquiring an additional 20,706 shares during the period. Millennium Management LLC grew its stake in Brainsway by 69.6% during the 3rd quarter. Millennium Management LLC now owns 39,841 shares of the company’s stock valued at $600,000 after purchasing an additional 16,354 shares during the last quarter. Finally, Centiva Capital LP acquired a new position in shares of Brainsway in the third quarter valued at about $181,000. Institutional investors own 30.11% of the company’s stock.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.